DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...
PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...
Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...
Medical Device Network on MSN3d
Analysts say Dexcom’s FDA warning unlikely to impact 2025 revenueDexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
The recent selloff of U.S. equities continued at midday on fears the U.S. economy could be heading toward a recession. The Nasdaq sank 3%, the S&P 500 dipped about 2%, and the Dow Jones Industrial ...
The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...
Key Takeaways DexCom received a warning letter from the Food and Drug Administration following inspections of two of its ...
Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...
DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.
FOX21 News has learned alternative ways people are getting around the shortage of the medical device called the Dexcom, a ...
DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback